Terry Heiman-Patterson, MD, Professor of Neurology at the Lewis Katz School of Medicine at Temple University, spoke with PhillyVoice about the results of the phase 2 trial for AMX0035, a treatment for amyotrophic lateral sclerosis (ALS) that combines two existing drugs, sodium phenylbutyrate and tauroursodeoxycholic acid, to target two different facets of the disease’s progression. Dr. Heiman-Patterson was the principal investigator at Temple.
IMPORTANT: Beginning at 8:00 AM on September 3, Temple University Hospital – Main Campus (Broad and Ontario Streets) will no longer provide Labor and Delivery services. All childbirth services will be relocated to our new hospital location.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH
Related News
Dr. Anjali Vaidya Participates in Q&A with Healio on Novel Screening Tool Developed at Lewis Katz School of Medicine Which Shows Significant Promise for Improving Detection of Pulmonary Arterial Hypertension
Posted July 24, 2025
Anjali Vaidya, MD, FACC, FASE, FACP, Director of the Advanced Pulmonary Hypertension, Right Heart Failure & Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program at Temple University Hospital, participated in a Q&A interview with Healio.
View DetailsDr. Ahmed Sadek Provides Perspective for Medscape Article on Report Analyzing PAH Incidence, Mortality Rates at National, Regional and Global Level
Posted July 24, 2025
Ahmed S. Sadek, MD, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University, provided perspective for a Medscape article on a report published in Frontiers in Public Health in which researchers analyzed data on pulmonary arterial hypertension (PAH).
View Details